Cutting to the chase with CRISPR

Huntington’s disease (HD) is caused by a repetition of the genetic letters C-A-G in the huntingtin gene. People who won’t develop HD have 35 or fewer CAGs, whereas people who go on to develop HD have 36 or more. Because the cause of HD is so clear, scientists have long been chasing a powerful idea:  What if we could remove the mutant gene?

A new study in Science Advances takes a major step in that direction. Using CRISPR gene editing, researchers were able to directly remove the mutant huntingtin gene in the brains of HD mice – leading to long-lasting improvements in brain health, movement, and lifespan.

Going upstream: targeting the source of the problem

DNA stores the cell’s genetic instructions, which are copied into an RNA message that is used to make proteins, the molecules that do the actual work within cells. The extra CAGs in the huntingtin gene lead to an expanded protein that is believed to derail the inner workings of cells.

Most current therapeutic strategies for HD aim to lower levels of huntingtin RNA and protein. These include approaches like antisense oligonucleotides (ASOs) or RNA interference (RNAi), which act at the RNA level – after the gene has already been read and copied.

CRISPR works differently. Instead of reducing the message or cleaning up the protein, CRISPR aims to change the DNA itself. This makes it a particularly attractive approach for HD, where a single faulty gene drives the entire disease.

CRISPR: molecular scissors with a built-in GPS

To understand why this recently published study is exciting, let’s take a closer look at how CRISPR works.

At its core, CRISPR is a way to edit DNA directly inside cells. But it’s not random – it’s precisely targeted. Think of it as a pair of molecular scissors guided by a GPS. DNA is incredibly long and densely packed – like a gigantic instruction manual. CRISPR needs a way to locate the exact spot to edit.

It uses a guide RNA, which acts like a search term. This small piece of RNA is designed to match a specific DNA sequence—in this case, part of the huntingtin gene. Like using “find” in a massive document, the guide RNA scans the genome until it finds its perfect match.

Once the target is found, the guide RNA brings in a protein called Cas9 – the actual “scissors.” Cas9 cuts both strands of DNA at that precise location. This creates a break that the cell must urgently repair. When cells repair the cut, they often introduce small errors. These tiny changes can disrupt the gene, preventing it from working properly.

In this study, the researchers targeted a region just before the disease-causing CAG repeat expansion in the HTT gene. And here’s the key idea: If the huntingtin gene is disrupted, it can no longer produce the RNA or protein.

A safer design: CRISPR that switches itself off

One of the biggest challenges with gene editing is safety.

If CRISPR stays active too long, it could cut unintended parts of the genome. To reduce this risk, the researchers designed a self-inactivating CRISPR system.

This means that CRISPR edits the gene and then turns itself off shortly after.

Think of it like a saw with an automatic safety shut-off—it cuts what it needs to, then immediately powers down to avoid causing extra damage.

Testing CRISPR in an HD mouse model

To test this approach, the researchers used a mouse model carrying a human version of the mutant huntingtin gene with a very long repeat expansion.These HD mice typically develop problems with coordination, balance, and movement, and clumps of huntingtin protein (aggregates) build up in their brain cells.

They delivered the CRISPR system directly into the brain using a viral vector, a modified virus that can enter cells, but is engineered to be harmless. This specialized packaging allowed the researchers to target regions most affected in HD, like the striatum and cortex.

The results were striking. Mutant huntingtin levels dropped by 60–90% and aggregates were reduced by up to 90%. These aggregates are a hallmark of HD pathology, and their reduction suggests a major improvement at the cellular level.

After CRISPR treatment, gait abnormalities improved, motor coordination increased and hyperactive, repetitive movements were reduced. Beyond the brain, treated mice showed reduced weight loss and extended lifespan, approaching that of healthy animals.

One of the most encouraging findings was that CRISPR was effective at different stages of disease. Administering the CRISPR system to the mice before symptoms began led to strong prevention of HD-like movement problems and fewer aggregates. When the mice received the viral vector as symptoms were just beginning, they showed clear improvements. But even when given after symptoms were established, there seemed to be meaningful benefits.

This suggests that even after the disease has begun, targeting the HD gene itself can still make a difference. 

Looking ahead

This study shows that editing the huntingtin gene with a self-inactivating CRISPR system can reduce toxic protein, improve symptoms, and extend lifespan in HD mice – even when treatment begins after disease onset. These results highlight the potential of gene editing to target the root cause of Huntington’s disease in a long-lasting way.

However, several key challenges remain before this approach could be used in people. Ensuring safety is critical, as unintended DNA edits could have serious consequences in humans. Delivering gene-editing tools across the human brain – which is around 1,000 times larger than a mouse brain – also remains a major hurdle. In addition, most people with HD carry both a healthy and a mutant copy of the gene, so therapies need to be developed to target only the harmful version. Finally, moving from successful experiments in mice to safe and effective treatments in humans requires many additional scientific and regulatory steps.

Together, these findings represent an important step forward, while also underscoring that more work is needed before CRISPR-based therapies can become a reality for people with HD.

Summary

• Huntington’s disease is caused by a single faulty gene—making it a strong candidate for gene-editing therapies like CRISPR.
• Researchers used CRISPR “molecular scissors” to cut and disrupt the mutant huntingtin gene directly in the brain.
• The team developed a self-inactivating CRISPR system that switches itself off after editing, improving safety.
• This approach reduced toxic protein levels by up to 90% and improved movement, behavior, and lifespan in HD mice.
• Benefits were seen even when treatment was given after symptoms had started, highlighting the potential for long-lasting therapies that target the root cause of HD.